Nucleome
6 known investors
Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.
Investors · 6
Competitors · 10
by search overlap
Alterome Therapeutics, Inc.32 shared keywordsAlterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.
Immunome32 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Noveome Biotherapeutics29 shared keywordsNoveome is a clinical-stage biopharmaceutical company developing ST266, a multi-targeted secretome containing hundreds of biologically active proteins designed for neuroprotection, inflammation modulation, and tissue healing. The company is investigating ST266's potential across ophthalmology, neurology, dermatology, and other therapeutic areas.
Myome25 shared keywordsMyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.
Cellanome25 shared keywordsCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.
OneOme18 shared keywordsOneOme is a precision medicine company that provides pharmacogenomics testing and analytics to healthcare providers, helping them optimize medication selection based on patients' genetic profiles. Co-founded by Mayo Clinic, the company serves healthcare teams and institutions globally seeking to improve patient outcomes and reduce costs through personalized medication decisions.
nChroma Bio17 shared keywordsnChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.
Sequome16 shared keywordsSequome uses AI to engineer biological sequences for developing therapeutics, based on its sequence-to-function model called Gene Genie. The company has collaborated with large pharmaceutical firms and Google DeepMind in the drug discovery and biotechnology space.
Freenome15 shared keywordsFreenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.
Etiome15 shared keywordsEtiome develops stage-specific medicines by applying single-cell omics and artificial intelligence to map disease progression and identify disease-modifying targets at early biological inflection points for preemptive intervention. Founded in 2021 out of Flagship Pioneering's Preemptive Health and Medicine initiative, the biotech company focuses on treating or reversing disease before it advances to later stages.
Companies competing with Nucleome for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Nucleome do?
- Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.
- Who are Nucleome's investors?
- Nucleome's investors include M Ventures, Oxford Science Enterprises, Pfizer Venture Investments, British Patient Capital, JJDC, Pfizer Ventures.